FDA Oncology Therapeutics Office Planned; Drug, Biologics Units Will Merge
Executive Summary
FDA is understood to be finalizing a plan for a new office of cancer therapeutics that would merge the current drug and biologics review groups within the Center for Drug Evaluation & Research's Office of New Drugs
You may also be interested in...
FDA Oncology Therapeutics Office Will Contain Three Divisions
FDA's proposed oncology therapeutics office will be organized into three divisions, Center for Drug Evaluation & Research Medical Policy Director Robert Temple, MD, said June 17 during a Drug Information Association meeting in Washington, D.C
FDA Oncology Therapeutics Office Will Contain Three Divisions
FDA's proposed oncology therapeutics office will be organized into three divisions, Center for Drug Evaluation & Research Medical Policy Director Robert Temple, MD, said June 17 during a Drug Information Association meeting in Washington, D.C
CBER Oncology Group Will Work To Create Consistent Approach To Products
The Office of Cellular, Gene & Tissue Therapies' new oncology group will work to ensure coordination in approaches to oncology products throughout FDA